- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02712372
A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects
January 5, 2017 updated by: AstraZeneca
A Phase I, Randomised, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4831 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
This is a Phase I, first-in-human (FIH) study to assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of AZD4831 after single and multiple ascending doses in healthy male subjects
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This is a Phase I, FIH, randomized, single-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of AZD4831 after single (Part 1) and multiple (Part 2) ascending doses in healthy male subjects.
The study will be conducted at a single study center with a planned number of subjects of up to 125 healthy males, aged 18 to 50 years.
Study Type
Interventional
Enrollment (Actual)
104
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria
- Provision of signed and dated, written informed consent before any study specific procedures.
- Healthy male subjects aged 18 - 50 years, inclusive, with suitable veins for cannulation or repeated venipuncture.
- Have a body mass index (BMI) between 18 and 29.9 kg/m2, inclusive, and weigh at least 50 kg and no more than 100 kg inclusive.
- Provision of signed, written and dated informed consent for optional genetic/biomarker research.
- Subjects must be able to read, speak and understand the German language.
Exclusion Criteria:
- History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- Presence of infection(s) (particularly fungal infection), as judged by the investigator.
- History or current thyroid disease.
- Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational medicinal product (IMP).
- Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results, as judged by the investigator.
- Any positive result on screening for serum hepatitis B surface antigen (HBsAg), anti-hepatitis B core (anti-HBc) antibodies, hepatitis C antibody and human immunodeficiency virus (HIV).
- Abnormal vital signs
- Any clinically significant abnormalities in rhythm, conduction or morphology of the resting ECG and any clinically significant abnormalities in the 12-lead ECG, as considered by the investigator that may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology, particularly in the protocol defined primary lead or LV hypertrophy.
- Prolonged QTcF > 450 ms or shortened QTcF < 340 ms or family history of long QT syndrome.
- PR(PQ) interval shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular pre-excitation)
- PR (PQ) interval prolongation (> 200 ms) intermittent second (Wenckebach block while asleep is not exclusive) or third degree AV block, or AV dissociation
- Persistent or intermittent complete bundle branch block, incomplete bundle branch block, or intraventricular conduction delay with QRS > 110 ms. Subjects with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of, for example, ventricular hypertrophy or pre-excitation.
- ECG findings suggesting a metabolic or other non-cardiac condition that may confound interpretation of serial changes (such as hypokalemia).
- Known or suspected history of drug abuse, as judged by the investigator.
- Current smokers or those who have smoked or used nicotine products within the previous 3 months.
- History of alcohol abuse or excessive intake of alcohol, as judged by the investigator.
- Positive screen for drugs of abuse, cotinine (nicotine) or alcohol at screening or admission to the unit before the first administration of IMP.
- History of severe allergy/hypersensitivity or ongoing clinically significant allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4831.
- Excessive intake of caffeine containing drinks or food (e.g., coffee, tea, chocolate), as judged by the investigator.
- Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks before the first administration of IMP.
- Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks before the first administration of IMP or longer if the medication has a long half-life.
- Plasma donation within 1 month of screening or any blood donation/blood loss > 500 mL during the 3 months before screening.
- Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or 1 month after the last visit whichever is the longest.
- Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
- Involvement of any Astra Zeneca, PAREXEL or study site employee or their close relatives.
- Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
- Subjects who are vegans or have medical dietary restrictions.
- Subjects who cannot communicate reliably with the investigator.
Exclusion from the genetic research:
- Previous bone marrow transplant.
- Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1, Dose Level 1
Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions.
Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
|
AZD4831 1-50 mg/g oral suspension
|
Experimental: Part 1, Dose Level 2
Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions.
Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
|
AZD4831 1-50 mg/g oral suspension
|
Experimental: Part 1, Dose Level 3
Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions.
Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
|
AZD4831 1-50 mg/g oral suspension
|
Experimental: Part 1, Dose Level 4
Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions.
Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
|
AZD4831 1-50 mg/g oral suspension
|
Experimental: Part 1, Dose Level 5
Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions.
Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
|
AZD4831 1-50 mg/g oral suspension
|
Experimental: Part 1, Dose Level 6
Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions.
Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
|
AZD4831 1-50 mg/g oral suspension
|
Experimental: Part 2, Dose Level 1
Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
|
AZD4831 1-50 mg/g oral suspension
|
Experimental: Part 2, Dose Level 2
Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
|
AZD4831 1-50 mg/g oral suspension
|
Experimental: Part 2, Dose Level 3
Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
|
AZD4831 1-50 mg/g oral suspension
|
Placebo Comparator: AZD4831 Placebo
Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions. Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12 |
AZD4831 placebo oral suspension
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequencies of adverse events
Time Frame: From screening up to 10 days post final dose
|
To assess the safety and tolerability of single and multiple doses of AZD4831
|
From screening up to 10 days post final dose
|
Supine blood pressure (Part 1)
Time Frame: From screening up to 48 hours post dose
|
To assess change from baseline in supine blood pressure
|
From screening up to 48 hours post dose
|
Supine pulse rate (Part 1)
Time Frame: From screening up to 48 hours post dose
|
To assess change from baseline in supine pulse rate
|
From screening up to 48 hours post dose
|
Supine body temperature (Part 2)
Time Frame: From screening up to pre-dose Day 12
|
To assess change from baseline in supine body temperature
|
From screening up to pre-dose Day 12
|
12-lead electrocardiogram
Time Frame: From screening up to 10 days post final dose
|
To assess 12-lead electrocardiogram
|
From screening up to 10 days post final dose
|
12-lead electrocardiogram (cardiac telemetry)
Time Frame: From Day-1 up to 24 hours post final dose
|
12-lead electrocardiogram (cardiac telemetry)
|
From Day-1 up to 24 hours post final dose
|
Physical examination
Time Frame: From screening up to 10 days post final dose
|
To assess subject through a physical examination, including assessment of the general appearance, skin, cardiovascular, respiratory, abdomen, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, musculoskeletal and neurological systems.
|
From screening up to 10 days post final dose
|
To assess the subject through hematology laboratory assessment
Time Frame: From screening up to 10 days post final dose
|
To assess a subject through hematology laboratory assessment
|
From screening up to 10 days post final dose
|
Percentage of adverse events
Time Frame: From screening to 10 days post final dose
|
To assess the safety and tolerability of single and multiple doses of AZD4831
|
From screening to 10 days post final dose
|
Supine blood pressure (Part 2)
Time Frame: From screening up to 10 days post final dose
|
To assess change from baseline in supine blood pressure
|
From screening up to 10 days post final dose
|
Supine pulse rate (Part 2)
Time Frame: From screening up to 10 days post final dose
|
To assess change from baseline in supine pulse rate
|
From screening up to 10 days post final dose
|
Chemistry evaluations
Time Frame: From screening up to 10 days post final dose
|
including high-sensitivity C-reactive protein {hs-CRP} and thyroid panel
|
From screening up to 10 days post final dose
|
To assess the subject through urinalysis laboratory assessment
Time Frame: From screening up to 10 days post final dose
|
To assess a subject through urinalysis laboratory assessment
|
From screening up to 10 days post final dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Observed maximum plasma concentration, taken directly from the individual concentration-time curve (Cmax)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Time to reach maximum plasma concentration, taken directly from the individual concentration-time curve (tmax)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (λz)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Terminal half-life, estimated as (ln2)/λz (t1/2λz)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Area under the plasma concentration-curve over 24 hours (AUCτ)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Area under the plasma concentration-curve from time zero to the time of last quantifiable analyte concentration (AUC0-t)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Area under the concentration-time curve from time zero extrapolated to infinity (AUC)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Apparent clearance for parent drug estimated as dose divided by AUC (CL/F)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Mean Residence Time (MRT)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Apparent volume of distribution for parent drug at terminal phase (Vz/F)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Area under the plasma concentration-time curve from time zero to time of last quantifiable analyte concentration divided by the dose administered (AUC0-t/D)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Area under the plasma concentration-time curve from time zero extrapolated to infinity divided by the dose administered (AUC/D)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Observed maximum plasma concentration divided by the dose administered (Cmax/D)
Time Frame: From pre-dose up to 48 hours post dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Area under the plasma concentration-curve over the dosing interval divided by the dose administered (AUCτ/D) (Part 2 only)
Time Frame: From pre-dose up to 48 hours post final dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post final dose
|
Accumulation ratio calculated as AUCτ Day 12/ AUCτ Day 1 (Rac AUC) (Part 2 only)
Time Frame: From pre-dose up to 48 hours post final dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post final dose
|
Accumulation ratio calculated as Cmax Day 12/ Cmax Day 1 (Rac Cmax) (Part 2 only)
Time Frame: From pre-dose up to 48 hours post final dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post final dose
|
Temporal change parameter in systemic exposure (TCP) (Part 2 only)
Time Frame: From pre-dose up to 48 hours post final dose
|
To characterize the plasma pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post final dose
|
Amount of analyte excreted into the urine from time t1 to t2 [Ae(t1-t2)]
Time Frame: From pre-dose up to 48 hours post dose
|
Assessment of the urine PK following single and multiple doses of pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Cumulative amount of analyte excreted at time t [Ae(0-t)]
Time Frame: From pre-dose up to 48 hours post dose
|
Assessment of the urine PK following single and multiple doses of pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Fraction of dose excreted unchanged into the urine from time t1 to t2, estimated by dividing Ae(t1-t2) by dose [fe(t1-t2)]
Time Frame: From pre-dose up to 48 hours post dose
|
Assessment of the urine PK following single and multiple doses of pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Fraction of dose excreted unchanged into the urine from time zero to time t, estimated by dividing Ae(0-t) by dose [fe(0-t)]
Time Frame: From pre-dose up to 48 hours post dose
|
Assessment of the urine PK following single and multiple doses of pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Renal clearance, estimated by dividing Ae(0-t) by AUC(0-t) (CLR)
Time Frame: From pre-dose up to 48 hours post dose
|
Assessment of the urine PK following single and multiple doses of pharmacokinetics of AZD4831
|
From pre-dose up to 48 hours post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rainard Fuhr, Dr. med., PAREXEL Early Phase Clinical Unit Berlin, On the premises of Klinikum Westend, Haus 31, Spandauer Damm 130, 14050 Berlin, Germany
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2016
Primary Completion (Actual)
October 1, 2016
Study Completion (Actual)
October 1, 2016
Study Registration Dates
First Submitted
March 15, 2016
First Submitted That Met QC Criteria
March 15, 2016
First Posted (Estimate)
March 18, 2016
Study Record Updates
Last Update Posted (Estimate)
January 6, 2017
Last Update Submitted That Met QC Criteria
January 5, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D6580C00001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
Clinical Trials on AZD4831
-
AstraZenecaParexelCompleted
-
AstraZenecaCompletedHeart Failure With Preserved Ejection FractionUnited States, France, Netherlands, Belgium, Taiwan, Slovakia, Japan, Czechia, Hungary, Australia, Bulgaria, Poland, Russian Federation, Brazil, Denmark, Turkey, Sweden, Canada
-
AstraZenecaParexelCompletedHeart Failure With Preserved Ejection Fraction (HFpEF)United States
-
AstraZenecaTerminatedHeart FailureDenmark, Finland, Netherlands, United States, Sweden
-
Mayo ClinicNational Center for Advancing Translational Sciences (NCATS)Completed
-
AstraZenecaParexelCompleted
-
AstraZenecaRecruitingChronic Obstructive Pulmonary Disease (COPD)United States, Canada, Denmark, Germany, South Africa, Spain, United Kingdom, Italy, Argentina, Bulgaria, Mexico, Turkey, Poland, Netherlands
-
AstraZenecaCompletedNon-Cirrhotic Non-alcoholic Steatohepatitis With FibrosisDenmark, Italy, Spain, United States, Argentina, Sweden, Mexico, Norway, Portugal
-
AstraZenecaParexelCompletedCardiovascular DiseaseUnited States
-
AstraZenecaQuotient SciencesCompletedCardiovascular DiseaseUnited Kingdom